Login / Signup

Reversible cicatricial ectropion associated with EGFR inhibitors.

Stacy Scofield-KaplanJames TodaroBryan J Winn
Published in: Orbit (Amsterdam, Netherlands) (2018)
The management of cicatricial ectropion resulting from epidermal growth factor receptor (EGFR) inhibitors is unclear. We describe two cases of bilateral cicatricial ectropion following the use of an EGFR inhibitor who were treated with oral doxycycline, topical ophthalmic steroid and antibiotic ointment to the eyelids, and topical facial steroid cream with lubrication. The first case resolved with discontinuation of panitumumab infusions along with institution of the aforementioned regimen. However, it is unclear whether the resolution was from discontinuation of the infusions or from the instituted regimen. The second case resolved without a dose adjustment of cituximab. This case may provide support for the use of this regimen prior to discontinuation of the offending agent, as there was a successful outcome without alteration of the infusions. Additional cases are necessary to determine if this is a successful means of treating bilateral lower-lid cicatricial ectropion from EGFR inhibitors.
Keyphrases
  • epidermal growth factor receptor
  • tyrosine kinase
  • advanced non small cell lung cancer
  • small cell lung cancer
  • case report
  • soft tissue